Positive opinion on Calliditas' Alport Syndrome drug from EMA 09-Oct-2023 By Liza Laws Calliditas Therapeutics AB announced on Friday (October 5) that the European Medicines Agency (EMA) has issued a positive opinion on the company’s drug, setanaxib in Alport Syndrome (AS).